The National Institutes of Health's National Institute on Drug Abuse is hiring a senior science writer-editor (technical writer-editor, GS 12 or 13). The senior science writer-editor will write engaging, accurate and informative content for NIDA web site pages, infographics, video scripts, blogs, reports, and more. Candidates can learn more about this position and apply here: Link for the public: https://loom.ly/lni1wHQ Link for current/former Federal employees or other status applicants: https://loom.ly/ixuRjss Applications are due July 26, 2024. The vacancy will close after the first 200 applications have been received.
The National Institute on Drug Abuse (NIDA)
Research Services
North Bethesda, Maryland 79,919 followers
Comment Policy: https://nida.nih.gov/comment-policy
About us
Official LinkedIn page of The National Institute on Drug Abuse. NIDA's mission is to advance science on drug use and addiction and to apply that knowledge to improve individual and public health. Engagement ≠ Endorsement Comment Policy: https://nida.nih.gov/comment-policy Privacy Policy: https://nida.nih.gov/privacy/how-nida-uses-third-party-web-sites-applications
- Website
-
https://nida.nih.gov/
External link for The National Institute on Drug Abuse (NIDA)
- Industry
- Research Services
- Company size
- 201-500 employees
- Headquarters
- North Bethesda, Maryland
- Type
- Government Agency
- Founded
- 1974
- Specialties
- Addiction Research, Research Training, and Research Funding
Locations
-
Primary
Three White Flint North
11601 Landsdown Street
North Bethesda, Maryland 20892, US
-
251 Bayview Boulevard
Baltimore, MD 21224, US
Employees at The National Institute on Drug Abuse (NIDA)
Updates
-
🆕 from #NIDA & colleagues in The Journal of Clinical Psychiatry: Prescription opioid use disorder among adults reporting prescription opioid use with or without misuse in the United States. Authors say, moderate-to-severe prescription opioid use disorder is more frequent among adults who report misusing prescription opioids. However, 62% of adults with prescription opioid use disorder do not report prescription opioid misuse, suggesting that adults who are treated with prescription opioids and report no misuse could be at risk for developing prescription opioid use disorder. Read more: https://loom.ly/okcjkvE Substance Abuse and Mental Health Services Administration (SAMHSA) Centers for Disease Control and Prevention
-
The National Institute on Drug Abuse (NIDA) reposted this
NIH is taking steps to re-envision the postdoctoral training experience, but the feedback of the biomedical research community is a crucial part of this process. Among the actions under consideration are: ➡️Limiting the amount of time a postdoctoral scholar can be supported by NIH funds to five years to speed transition into research careers. ➡️ Shorten the eligibility window and refocus review criteria for a key mentored career development award (K99/R00) to facilitate more rapid transition of postdoctoral scholars. ➡️Enhancing training and professional development for postdoctoral scholars and their mentors. Share your feedback by October 23, 2024: https://go.nih.gov/amqQ7DD
-
-
The NIH HEAL Initiative® seeks input on future research priorities and how scientific research can continue to address the urgent public health challenges of opioid use disorder, overdose, and pain. Your feedback will help inform HEAL research! Please send an email to [email protected] with “HEAL RFI” in the subject line by July 31, 2024. #nihHEALinitiative #RFI Learn more: go.nih.gov/mcoqY3J
-
-
Researchers, check out this 🆕 The National Institutes of Health funding opportunity: Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required). 📆 Letters of intent due October 27. Applications due November 27. https://go.nih.gov/aHEovQM
-
-
Researchers and entrepreneurs, check out this 🆕 The National Institutes of Health #FundingOpp: Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use. This funding opportunity encourages grant applications from small business concerns proposing research and development of accessible and affordable solutions targeted to improve health outcomes and reduce the impact of adverse health consequences of non-disordered drug use. 📆 Letter of Intent due November 2. Applications due December 2. Small Business Technology Transfer Grant: https://loom.ly/zCeVlJo Small Business Innovation Research Grant: https://loom.ly/TSwi29Q
-
Don't Forget! 📣 Applications for two funding opportunities from The National Institutes of Health Advancing Prevention Research for Health Equity (ADVANCE) initiative are due August 5, 2024. 📅 The funding opportunities support research on multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. The Research Network will include a Coordinating Center that will provide overarching support and guidance to the network. Learn more about the Research Network and apply: https://lnkd.in/gmQFDyAJ Learn more about the Coordinating Center and apply: https://lnkd.in/eGu2sWMj
-
-
Reminder: Response due by August 1, 2024 🗓️ Request for Information (RFI): BRAIN Initiative: Opportunities and Challenges for Coordinated Neural Stimulating and Recording Efforts to Advance Understanding of Human Neuroscience and Behavior http://dlvr.it/T6Msc6
-
Join NIDA, National Institute of Allergy and Infectious Diseases (NIAID), HHS Administration for Strategic Preparedness and Response , and Biomedical Advanced Research and Development Authority (BARDA) December 17–18 for a trans-agency meeting on: ✅ Current research on opioid- and other drug-induced toxicities ✅ Emerging therapeutic strategies and treatment options to reverse severe morbidity and mortality ✅ Knowledge gaps on how opioids, respiratory depressants, and related drug combinations potentially impact persistent or delayed morbidities ✅ FDA regulatory considerations for new technology and treatment approaches This scientific meeting will bring together subject matter experts from the public and private research and drug development communities to discuss the current state of the field and provide a forum for networking and future strategic partnerships. Register: https://lnkd.in/eKdmUx7G
-
-
🆕 in Nora's Blog: We should leverage the successes of HIV care to prevent overdose mortality. In the blog, NIDA Director Dr. Nora Volkow and National Institute of Allergy and Infectious Diseases (NIAID) Director Dr. Jeanne Marrazzo discuss how HIV and substance use have been linked since the HIV epidemic began & how delivering naloxone and overdose education in HIV care settings is an obvious and relatively easy way to prevent overdose deaths.
We should leverage the successes of HIV care to prevent overdose mortality
The National Institute on Drug Abuse (NIDA) on LinkedIn